Rubia yunnanensis

Other Names

Root of Yunnan MadderRubia sikkimensis var. yunnanensisRubia sikkimensis var. yunnanensis Franch. ex DielsRubia ustulataRubia ustulata DielsXiao hong shenXiaohongshenYunnan madder小活血小红参小红药小茜草滇紫参滇茜草紫参紫参（小红参）

Synopsis

Rubia yunnanensis Diels: A Comprehensive Encyclopedic Reference

1. Identity and Botanical Classification

Scientific Nomenclature and Taxonomy

Rubia yunnanensis Diels (family Rubiaceae) is a plant used in traditional Chinese medicine, first formally described by Ludwig Diels in 1912. It is endemic to Yunnan and Sichuan provinces, China; a perennial herb whose stem is usually clumped, sometimes procumbent, 10–50 cm in height, with a rootstock and somewhat thickened storage roots that are red in color — a feature that gave rise to the local name xiaohongshen (literally, "small red ginseng").

Phylogenomic analysis has found that R. yunnanensis is closely related to R. cordifolia. Within the Chinese pharmacopoeial tradition, Qiancao (madder root) comprises five closely related species: Rubia cordifolia L., Rubia yunnanensis Diels., Rubia wallichiana Decne., Rubia schumanniana Pritz., and Rubia magna P.G. Xiao. Due to their similar morphological characteristics, alternative species are frequently substituted for R. cordifolia L. in traditional medicine; however, the latest National Pharmacopoeia of China only exclusively recognizes R. cordifolia L. as the official medicinal source.

Common Names and Synonyms

Roots and rhizomes of R. yunnanensis, known as Xiaohongshen in China, have been used as a Traditional Chinese Medicine (TCM). Rubia yunnanensis is the dried root and rhizome of R. yunnanensis Diels, a Rubiaceae plant and a unique indigenous medicine in Yunnan, China. The roots and rhizomes are also served as a substitute for the TCM Qiancao indexed in the Chinese Pharmacopoeia.

Medicinal Part and Natural Occurrence

The roots of R. yunnanensis are used as medicines and natural dyes in Yunnan province. Rubia yunnanensis Diels is an important medicinal herb mainly distributed in Yunnan Province, Southwest China. The roots and rhizomes of Rubia plants, also called madder, are generally rich in quinones including anthraquinones and naphthoquinones, therefore mostly presenting fuchsia or orange red color, and have been used as popular natural plant dyestuffs for clothes and food items in industry.

Common Dosage Forms and Preparations

In research settings, the plant material is processed into several standard preparations. An alcohol extract of Rubia yunnanensis (RY-A) is obtained by soaking 500 g of powdered Rubia yunnanensis in 95% ethanol for 24 hours, then heating and refluxing at 60°C, and repeatedly soaking, heating and refluxing for four times. The roots have also been used as popular natural plant dyestuffs for clothes and food items in industry. In experimental studies, both methanol and ethyl acetate fractions have been employed alongside the crude ethanol extract, as well as isolated pure compounds. Phytochemical studies have revealed that Rubiaceae-type cyclopeptides (RAs), quinones, and arborinane-type triterpenoids are the main types of chemical constituents in Xiaohongshen.

2. Traditional and Historical Use

Culture, Time Period, and Documentation

The application of R. yunnanensis has been recorded in the Southern Yunnan Materia Medica (Dian Nan Ben Cao) for the treatment of cardiovascular and gastrointestinal disease, menstrual disorder, and trauma for hundreds of years. The Southern Yunnan Materia Medica (Dian Nan Ben Cao) is the earliest and most complete local Bencao (materia medica) text, written in approximately the fourteenth to fifteenth century by Lan Mao, a physician of the Ming Dynasty. It records the medicinal materials of the Yunnan district with distinct national and local folk characteristics.

Herbs from Yunnan are widely used in the prevention and treatment of cardiovascular, gastrointestinal and traumatic diseases and have been documented in the Southern Yunnan Materia Medica and applied for hundreds of years.

Therapeutic Indications in Traditional Practice

R. yunnanensis roots and rhizomes have been used as a Traditional Chinese Medicine (TCM) for the treatment of rheumatism, contusion, menoxenia, tuberculosis, anemia, and lipoma.

Within the context of TCM, R. yunnanensis serves as a therapeutic agent for the treatment of rheumatism, menstrual disorders, tuberculosis, hematemesis, vertigo, insomnia, and anemia.

The roots of Rubia yunnanensis Diels (Rubiaceae) have been used as an alternative for Rubia cordifolia for the treatment of various diseases including cardiovascular disease and metabolic disease for a long history in traditional Chinese medicine.

R. yunnanensis has pharmacological actions, such as anti-myocardial ischemia, anti-oxidation, and anti-platelet activity, documented in traditional records.

Relationship to Related Species in the Pharmacopoeia

In Chinese traditional medicine, the roots of R. cordifolia L. have been used for their antiproliferative and anti-inflammatory activity in treating rheumatism, inflammation, psoriasis, and other conditions, and many biologically active compounds could be obtained from the genus Rubia. R. yunnanensis has historically been employed as a close substitute for this pharmacopoeial species, with both sharing overlapping indications. The roots and rhizomes of Rubia plants, including Rubia cordifolia, were recorded as a traditional Chinese medicine in the Chinese Pharmacopeia and have been widely used for the treatment of menoxenia, rheumatism, contusions, and tuberculosis.

3. Phytochemistry: Key Constituents and Active Compounds

Numerous studies have verified that over 120 compounds, primarily triterpenoids, anthraquinones, and cyclic peptides, have been isolated from R. yunnanensis, exhibiting diverse biological and pharmacological activities, such as cytotoxic, antihyperlipidemic, anti-inflammatory, and anti-tumor efficacy.

3.1 Rubiaceae-Type Cyclopeptides (RAs)

Rubiaceae-type cyclopeptides (RAs) are a type of plant cyclopeptides from the genus Rubia that have garnered significant attention owing to their unique bicyclic structures and remarkable antitumor activities. RAs are a kind of homodicyclohexapeptides, which have attracted great interest due to their distinctive bicyclic structural feature.

Among the specific cyclopeptides isolated from R. yunnanensis, the following have been characterized in the peer-reviewed literature:

Rubiyunnanins A and B: Two novel cyclic hexapeptides, named rubiyunnanins A (1) and B (2), were isolated from the roots of Rubia yunnanensis Diels. Possible biosynthetic pathways for RAs, 1, and 2 were proposed. Compound 2 showed moderate cytotoxicities against 11 cancer cell lines and inhibited nitric oxide (NO) production in LPS and IFN-γ-induced RAW 264.7 murine macrophages.
Rubiyunnanins C–H: All compounds (rubiyunnanins C–H and related known compounds 1–11) not only exhibited cytotoxic activities against a panel of eleven cancer cell lines with IC₅₀ values ranging from 0.001 to 56.24 μM, but also exerted inhibitory activities against nitric oxide (NO) production in LPS and IFN-γ-induced RAW 264.7 murine macrophages. Furthermore, compounds 2 and 7–10 significantly inhibited TNF-α-induced NF-κB activation in HEK-293-NF-κB luciferase stable cells with IC₅₀ values of 35.07, 0.03, 1.69, 12.64, and 1.18 μM, respectively.
RA-V (deoxybouvardin): RA-V (deoxybouvardin), a unique natural cyclopeptide isolated from the medicinal plant Rubia yunnanensis, has been reported to exhibit potent anti-tumor activities in a variety of cancer cell lines. In particular, RA-V could induce cell apoptosis via the mitochondrial pathway and promote the loss of mitochondrial membrane potential (MMP) and the release of cytochrome c (Cyt c).
RA-XII: RA-XII is a natural cyclopeptide isolated from the traditional Chinese medicine Rubia yunnanensis, exerting anti-inflammatory and anti-tumor activities.

RAs are validated to be responsible for various significant bioactivities, including NF-κB inhibitory activity, induction of apoptosis and inhibition of autophagy, and inhibition of tumor growth and metastasis.

3.2 Anthraquinones and Quinones

The quinones are responsible for many biological activities — including cytotoxicity, antioxidant activity, antibacterial activity, hepatoprotective effect, inhibition of platelet aggregation, and hypolipidemic effect — of Xiaohongshen.

Among the characterized anthraquinones:

2-Methyl-1,3,6-trihydroxy-9,10-anthraquinone (MTA/MTHA): MTA (2-methyl-1,3,6-trihydroxy-9,10-anthraquinone), one of the major components isolated from Rubia yunnanensis, exhibited inhibitory activity on the proliferation of several human cancer cell lines. Arborinane-type triterpenoids, especially rubiarbonone C (16), and an anthraquinone, 2-methyl-1,3,6-trihydroxy-9,10-anthraquinone (MTHA) (22), were identified as the main active compounds responsible for antihyperlipidemic activity.
Novel anthraquinones: Twelve new arborinane-type triterpenoids (1–12) and four new anthraquinones (13–16), together with 50 known compounds, were isolated from the roots of Rubia yunnanensis.
Rubianthraquinone-3-O-β-glucopyranoside: Two undescribed compounds, rubianthraquinone-3-O-β-glucopyranoside (1) and 28-hydroxyrubiyunnanol A (2), along with thirteen known analogues (3–15), were isolated from the roots of Rubia yunnanensis.

3.3 Arborinane-Type Triterpenoids

Five new triterpenoids — rubiarbonones D (1), E (5), and F (2), and rubiarbosides F (3) and G (4) — together with nine known compounds, were isolated from the roots of Rubia yunnanensis. Their structures were elucidated by spectroscopic methods. The antiplatelet aggregation activities of several rubiarbonone and rubiarbonol analogues were also investigated. Rubiyunnanol C (5) is the first example of an arborinane-type triterpenoid with a double bond at C-8-C-9.

3.4 Naphthohydroquinones

Four new naphthohydroquinones — rubinaphthins A (1), B (2), C (3), and D (4) — together with 11 known compounds, were isolated and characterized from the roots of Rubia yunnanensis. These naphthohydroquinone structures contribute to the quinone-related bioactivities documented for the species.

3.5 Other Identified Compounds

Phytochemical studies showed that Rubiaceae-type bicyclic hexapeptides, anthraquinones, and triterpenoids are the major types of chemical constituents of this plant. Additional minor constituents identified in some extracts include compounds with antioxidant and anti-inflammatory properties such as α-tocopherol, lupeol acetate, squalene, and rubiyunnanin H.

4. Mechanisms of Action

4.1 NF-κB Pathway Inhibition

Nuclear factor κB (NF-κB) signaling plays a critical role in inflammation, angiogenesis, and apoptosis. By screening compound libraries using an NF-κB-dependent luciferase reporter, RA-V was identified as the best NF-κB inhibitor. Further experiments demonstrated that RA-V interrupted the TAK1–TAB2 interaction and targeted TAK1 in this pathway. Moreover, RA-V prevented endotoxin shock and inhibited NF-κB activation and tumor growth in vivo.

These findings clarify the mechanism of RA-V on the NF-κB pathway and might account for the majority of known bioactivities of RA-V, which will help RA-V develop as new anti-inflammatory and anti-tumour therapies.

4.2 Apoptosis Induction and Cell Cycle Arrest

The over-expression of p21 and down-expression of cyclin B1 caused by MTA inactivated the Cdc2-cyclin B1 complex of the G2/M checkpoint and finally caused G2/M arrest in HeLa cells. This study demonstrated that MTA is a potential anti-cancer component of R. yunnanensis, a folk anti-cancer herb used in Yunnan, China.

Plant cyclopeptide RA-V kills human breast cancer cells by inducing mitochondria-mediated apoptosis through blocking the PDK1/AKT interaction.

4.3 Antiangiogenic Effects

Cyclopeptide RA-V inhibits angiogenesis by down-regulating ERK1/2 phosphorylation in HUVEC and HMEC-1 endothelial cells. RA-V also inhibits cell adhesion and invasion in both estrogen receptor positive and negative breast cancer cells via PI3K/AKT and NF-κB signaling pathways.

4.4 Antiplatelet and Lipid-Lowering Mechanisms

The antiplatelet aggregation activities of rubiarbonone A and rubiarbonols A and B have been investigated with a standard protocol. With respect to lipid lowering, methanol extract and ethyl acetate fraction of Rubia yunnanensis potently decreased triglyceride accumulation in HepG2 cells, and the methanol extract of Rubia yunnanensis (125, 250, and 500 mg/kg) significantly inhibited TG elevation in a dose-dependent manner in olive oil-loaded mice. Based on these findings, it was proposed that the extract of Rubia yunnanensis and its active components, arborinane-type triterpenoids and the free anthraquinone, might be beneficial in the treatment and prevention of hyperlipidemic disease.

4.5 Cardiovascular and Endothelial Protection via PI3K/AKT

Ethanol extract of R. yunnanensis reduced lipid levels, intima damage, and carotid lipid accumulation and increased p-PI3K/PI3K and p-AKT/AKT protein levels in ApoE−/− mice fed a high-fat diet for 12 weeks. It was hypothesized that these effects are achieved by regulation of the phosphatidylinositol-3-kinase/protein kinase B signaling pathway.

4.6 Neuroprotective and Antioxidant Mechanisms

RY-A (ethanol extract of R. yunnanensis) induced neuroprotective effects by increasing the production of key proteins involved in ferroptosis inhibition, such as SLC7A11, SLC3A2, GSS, and GPX4, while increasing antioxidant enzyme activities and alleviating oxidative stress. Specifically, RY-A inhibited oxidative stress and ferroptosis by activating the System Xc−/GSH/GPX4 pathway and balancing iron metabolism, thereby attenuating chronic cerebral hypoperfusion (CCH)-induced neurological damage and cognitive deficits.

4.7 Nrf2-Mediated Resistance Reversal

A new connection between acquired resistance to the KRAS G12C inhibitor adagrasib (MRTX849) and nuclear factor erythroid 2-related factor 2 (Nrf2) was identified in colorectal cancer cells. Expression levels of Nrf2 and GLS1 proteins were substantially elevated in CRC cell lines with acquired resistance to MRTX849 compared with their corresponding parental cell lines. RA-V, one of the natural cyclopeptides isolated from the roots of Rubia yunnanensis, was discovered to restore the response of resistant CRC cells to MRTX849.

5. Scientific Evidence by Area of Use

5.1 Oncology / Anticancer Activity

Evidence level: Preclinical (in vitro and in vivo animal models); no human clinical trials identified.

RA-VII, a Rubiaceae-type cyclopeptide, was reported to have undergone phase I clinical trials at the NCI as an anticancer drug in Japan in the 1990s. This is significant because RA-VII was obtained from related Rubia plants. For R. yunnanensis specifically, research has remained at the preclinical stage.

In cell-line studies, all compounds from rubiyunnanins C–H exhibited cytotoxic activities against a panel of eleven cancer cell lines with IC₅₀ values ranging from 0.001 to 56.24 μM.

Compounds 14 and 15 (isolated from R. yunnanensis) demonstrated potent inhibition on HePG2 cell growth, whereas compounds 6, 10, and 11 exhibited pronounced suppression on the production of IL-6 and liberation of TNF-α in LPS-stimulated macrophage cultures.

Regarding resistance to cancer therapy, RA-V, one of the natural cyclopeptides isolated from the roots of Rubia yunnanensis, could restore the response of resistant colorectal cancer cells to adagrasib. This is in vitro cell-line data only and has not been validated in humans.

The anticancer activity of RA-V was found to remain unchanged before and after treatment of simulated gastric and intestinal fluids, indicating that RA-V was stable and could potentially be bioavailable when used orally, making it a possible drug candidate for cancer treatment. This represents preliminary pharmacokinetic support and not clinical proof.

In nanoparticle drug delivery experiments, multi-organelle-targeted, pH/cytochrome c dual-responsive nanoparticles were designed for combination therapy on resistant tumors. In this system (designated DGLipo NPs), doxorubicin was intercalated into the DNA duplex while cyclopeptide RA-V was doped into the pH-sensitive liposomal shells. After dual modification, the nanoparticles could successively deliver the two drugs into lysosome and mitochondria of cancer cells. Again, this is preclinical experimental research.

Summary: The anticancer evidence for R. yunnanensis is confined to cell lines and animal models. No peer-reviewed human clinical trials specific to R. yunnanensis extracts or isolated compounds in cancer treatment have been identified in the scientific literature to date.

5.2 Antihyperlipidemic / Lipid Metabolism

Evidence level: In vitro (HepG2 cells) and in vivo animal model; no human clinical trials identified.

Antihyperlipidemic effects of extracts and compounds of the roots of Rubia yunnanensis were studied in HepG2 cells and an in vivo model using olive oil-loaded mice. Methanol extract and ethyl acetate fraction of Rubia yunnanensis potently decreased triglyceride accumulation in HepG2 cells, and the methanol extract of Rubia yunnanensis (125, 250, and 500 mg/kg) significantly inhibited TG elevation in a dose-dependent manner.

Rubiarbonone C and MTHA were identified as the main active compounds responsible for antihyperlipidemic activity. Pharmacological studies in animal models also revealed that remedies containing Rubia yunnanensis are able to lower blood pressure and lipid levels.

Limitations: All evidence at this time is preclinical (cell lines and rodent models). Extrapolation to human metabolic disease requires clinical validation not yet available in the published literature.

5.3 Cardiovascular / Atherosclerosis

Evidence level: Animal model (ApoE−/− mouse); no human clinical data identified.

Ethanol extract of R. yunnanensis reduced lipid levels, intima damage, and carotid lipid accumulation, and increased p-PI3K/PI3K and p-AKT/AKT protein levels in ApoE−/− mice fed a high-fat diet for 12 weeks. Therefore, R. yunnanensis may be a promising option for treating atherosclerosis in the future. This is the conclusion of an animal study, not a clinical trial.

5.4 Anti-inflammatory Activity

Evidence level: In vitro (macrophage and cell-line models) and animal models; no human clinical trials identified.

Compounds 1, 2, 4, 6, 10, and 11 (isolated from R. yunnanensis) diminished the production of TNF-α and the release of IL-6 by LPS-induced RAW 264.7 macrophage cells.

RA-XII is a natural cyclopeptide isolated from Rubia yunnanensis, exerting anti-inflammatory and anti-tumor activities. The study explored the effects of RA-XII on LPS-induced acute kidney injury and the underlying molecular mechanism in TCMK-1 cells in vitro. RA-XII delayed animal death caused by LPS in mice, markedly attenuated kidney histological changes, and also reduced the serum uric acid, creatinine, BUN, and renal 8-OHdG.

5.5 Neuroprotective Activity

Evidence level: In vitro (HT22 neuronal cells) and animal model (rat CCH model); no human clinical trials identified.

The inhibitory and neuroprotective effects of Rubia yunnanensis alcohol extract (RY-A) on oxidative stress induced by oxygen-glucose deprivation/reoxygenation (OGD/R) in HT22 cells were investigated. Cultured HT22 cells were randomly divided into control, OGD/R, OGD/R + 100 µmol/L edaravone, and OGD/R + 10, 20, and 40 µg/mL RY-A groups.

In a rat model of vascular dementia, RY-A inhibited oxidative stress and ferroptosis by activating the System Xc−/GSH/GPX4 pathway and balancing iron metabolism, thereby attenuating CCH-induced neurological damage and cognitive deficits. Rubia yunnanensis has a long history of use as an intervention in cardiovascular and cerebrovascular diseases, but its effects and mechanisms of action on chronic cerebral hypoperfusion had not been reported prior to this 2025 study.

In the integrated transcriptomics and metabolomics investigations, the ferroptosis pathway ranked first among the co-enriched pathways, and the level of GSH was significantly increased after RY-A treatment.

Limitations: The neuroprotective evidence is entirely preclinical (cell cultures and rat models). These findings are hypothesis-generating and require clinical validation.

6. Body Systems and Health Areas Associated with Rubia yunnanensis

Based on the accumulated preclinical and traditional evidence, the following body systems have been investigated in the scientific literature:

Oncology / Hematological and Solid Tumors: Cytotoxic and antitumor efficacy has been demonstrated in preclinical models with compounds including RAs and anthraquinones.
Cardiovascular System: R. yunnanensis has pharmacological actions such as anti-myocardial ischemia, anti-oxidation, and anti-platelet activity documented in traditional records and corroborated in preclinical studies.
Metabolic System (Lipid Metabolism): Pharmacological studies in animal models revealed that remedies containing Rubia yunnanensis are able to lower blood pressure and lipid levels.
Immune / Inflammatory System: Anti-inflammatory activity has been demonstrated preclinically through inhibition of pro-inflammatory cytokines.
Nervous System / Neuroprotection: Vascular dementia, associated with chronic cerebral hypoperfusion, is characterized by memory impairment, cognitive decline, and behavioral changes, and R. yunnanensis has been studied in this context in animal models.
Musculoskeletal System: Traditional use includes rheumatism and contusion, with modern pharmacological studies beginning to explore related anti-inflammatory pathways.
Reproductive / Gynecological System: Menstrual disorders are among the traditional indications for R. yunnanensis within TCM.

7. Dosage Forms and Dosages Reported in Studies

No standardized or officially approved dosage for human use of R. yunnanensis as a dietary supplement or medicine has been established in the peer-reviewed or regulatory literature identified. The following dosages are reported strictly as described in the cited research studies:

Methanol extract (in vivo, mice — antihyperlipidemic): The methanol extract of Rubia yunnanensis at doses of 125, 250, and 500 mg/kg was administered to olive oil-loaded mice, producing dose-dependent inhibition of TG elevation.
Alcohol extract (in vitro, HT22 cells — neuroprotective): In vitro cultured HT22 cells were treated with OGD/R + 10, 20, and 40 µg/mL of RY-A (Rubia yunnanensis alcohol extract).
Hairy root culture production context: Due to its medicinal value and industrial importance, the demand for Xiaohongshen is rapidly increasing. Hairy root culture systems have been established to sustainably produce the plant's bioactive cyclopeptides and quinones.
Individual compound IC₅₀ values (in vitro): Rubiyunnanins C–H exhibited cytotoxic activities against cancer cell lines with IC₅₀ values ranging from 0.001 to 56.24 μM and inhibitory activities against NO production with IC₅₀ values ranging from 0.05 to 12.68 μM.

No clinical trials establishing a recommended human dose of crude R. yunnanensis extract have been identified in the peer-reviewed literature. Dosage information from traditional sources (e.g., Dian Nan Ben Cao) has not been reproduced in verified, peer-reviewed English-language publications retrievable from major scientific databases.

8. Safety Considerations

8.1 General Status of Safety Research

Dedicated clinical safety studies specific to Rubia yunnanensis in human populations have not been identified in the peer-reviewed literature. Safety considerations are derived from studies of the plant's constituent compound classes — particularly anthraquinones — and from general preclinical findings.

8.2 Mutagenicity and Carcinogenicity Concerns with Anthraquinones

The mutagenicity or carcinogenic potential of the active anthraquinones present in Rubia species is a matter of concern. At present, there is a lack of research and literature on the in vivo metabolism and metabolites of these components, so in terms of safe medication, the Absorption-Distribution-Metabolism-Excretion-Toxicity (ADMET) of these naturally occurring anthraquinones should be an urgent area of investigation.

8.3 In Silico Toxicity Predictions for Key Anthraquinones

Investigation of rubiadin toxicity was estimated using the variable closest neighbor (vNN)-ADMET web server. According to the program's prediction model, rubiadin (a key anthraquinone of the genus) can cause drug-induced liver damage, mutations, and mitochondrial dysfunction. These are in silico predictions and have not been confirmed in clinical settings; they nonetheless highlight the need for formal toxicity evaluation.

8.4 Toxicological Data on Anthraquinone Itself (Class-Level Data)

An acute toxicity test was performed in female Sprague Dawley (SD) rats, and the oral median lethal dose (LD₅₀) of anthraquinone was estimated to be greater than 5000 mg/kg body weight. When animals received 5.44 mg/kg BW or more of anthraquinone, hyaline droplet accumulation in the renal tubules was observed in both male and female rats, and anemia was observed in females. When the anthraquinone dose reached 174.08 mg/kg BW, mild hepatocellular hypertrophy around the central vein of the hepatic lobule and hypothyroidism were observed in female rats. During the recovery period, changes in clinical symptoms and parameters were considerably alleviated. These findings refer to the anthraquinone compound class broadly and have not been replicated using specific R. yunnanensis extracts.

8.5 Purpurin (Rubia-Derived Anthraquinone) Acute Toxicity Data

Oral administration of purpurin (1,2,4-trihydroxy-9,10-anthraquinone, an anthraquinone found in Rubia species) to mice revealed an LD₅₀ exceeding 2000 mg/kg. According to this criterion, purpurin was designated as a Category 5 toxicant, signifying a comparatively low degree of acute oral toxicity under established testing protocols. However, protracted treatment at elevated doses may pose a risk of organ-specific toxicity, particularly in the renal and urinary systems. The importance of meticulous long-term safety assessments and dose optimization in the development of purpurin-based therapies or nutraceuticals is emphasized by these findings.

8.6 Conservation and Supply Chain Considerations

Due to its medicinal value and industrial importance, the demand for Xiaohongshen is rapidly increasing. The species' natural wild populations in Yunnan and Sichuan are under pressure from overcollection. The metabolic differences among the five related Rubia species used as Qiancao remain poorly characterized, largely owing to the absence of systematic metabolomic studies. This means that adulteration or species substitution in commercial preparations cannot be reliably excluded without rigorous analytical verification.

8.7 Interactions

No peer-reviewed human pharmacokinetic interaction studies specific to Rubia yunnanensis extracts or their isolated compounds have been identified. Given the presence of potent NF-κB inhibitors (RA-V), antiplatelet-active triterpenoids, and anthraquinones with potential effects on drug-metabolizing enzymes, the theoretical potential for interactions with anticoagulants, immunosuppressants, and cytochrome P450 substrates warrants caution in the absence of definitive human data. The anthraquinone and quinone content creates potential for additive effects with other laxative or hepatotoxic agents, as noted in the broader anthraquinone literature.

9. Regulatory and Pharmacopoeial Status

The latest National Pharmacopoeia of China exclusively recognizes Rubia cordifolia L. as the official medicinal source for Qiancao, meaning that R. yunnanensis does not hold independent pharmacopoeial status in the current Chinese Pharmacopoeia despite its historical use as a substitute. Rubia yunnanensis Diels is a pivotal medicinal herb whose root has served as an alternative to Rubia cordifolia L. for centuries, a well-known TCM enlisted in the Chinese Pharmacopoeia. No entry for R. yunnanensis in the European Pharmacopoeia, WHO Monographs, ESCOP, German Commission E, or the USP was identified in the available literature.

10. Research Landscape and Evidence Gaps

Research on Rubia yunnanensis has grown substantially since the 2010s, primarily from research groups in Yunnan, Nanjing, and affiliated Chinese universities. Over 120 compounds have now been isolated and partially characterized for their biological activities. Despite this chemical richness, the field faces several critical gaps:

Absence of clinical trials: As of the available literature, no controlled clinical trials in human subjects evaluating any standardized extract or isolated compound of R. yunnanensis for any indication have been published.
Lack of ADMET data: There is a lack of research and literature on the in vivo metabolism and metabolites of the active anthraquinone components.
Metabolomic standardization: The metabolic differences among the related Qiancao species remain poorly characterized, largely owing to the absence of systematic metabolomic studies.
Bioavailability questions: While RA-V has shown stability in simulated gastrointestinal fluids, further evidence supporting oral bioavailability in therapeutics is needed before it can be confirmed as a drug candidate for cancer treatment.
Wild-population sustainability: The growing commercial demand and the narrow geographic distribution of R. yunnanensis create supply and quality-assurance challenges that hairy root culture technology is only beginning to address.

References

Health Conditions

Health conditions that Rubia yunnanensis may help support.

No conditions available.

Body Systems

Body systems that Rubia yunnanensis may help support.

No body systems available.